Androgen deprivation therapy and acute kidney injury in patients with prostate cancer undergoing definitive radiotherapy.
Journal
Prostate cancer and prostatic diseases
ISSN: 1476-5608
Titre abrégé: Prostate Cancer Prostatic Dis
Pays: England
ID NLM: 9815755
Informations de publication
Date de publication:
06 2023
06 2023
Historique:
received:
12
02
2021
accepted:
22
06
2021
revised:
12
06
2021
medline:
9
6
2023
pubmed:
24
11
2021
entrez:
23
11
2021
Statut:
ppublish
Résumé
Androgen deprivation therapy (ADT) is frequently utilized in conjunction with radiotherapy (RT) in the definitive management of prostate cancer. Prior studies have suggested an association between ADT use and acute kidney injury (AKI), however, these included heterogeneous populations undergoing a variety of treatments and relied on billing codes to ascertain the incidence of AKI. We analyzed a cohort of 27,868 veterans undergoing definitive RT + /- ADT for prostate cancer between 2001 and 2015 using the Veterans Affairs Informatics and Computing Infrastructure (VINCI). Exposure was defined as use of ADT within one year of diagnosis. The primary outcome was AKI, defined by an increase in serum creatinine to at least 1.5 times the baseline value. AKIs were classified as mild, moderate, or severe in accordance with international guidelines. A multivariate competing risks model was used to account for demographic and oncologic factors as well as medications and procedures known to influence the risk of AKI. Most (n = 18,754) men received RT alone; 9,114 men received RT + ADT. The incidence of AKI at two years after diagnosis was 10.5% in the RT + ADT group and 7.9% in the RT group (Gray's test p < 0.01). Multivariate analysis confirmed ADT usage was associated with an increased risk for any AKI (SHR = 1.24, 95% CI = 1.14-1.36, p < 0.01). ADT was also associated with an increased risk of mild AKI (SHR = 1.13, 95% CI = 1.01-1.27, p = 0.04) and moderate AKI (SHR = 1.45, 95% CI = 1.20-1.76, p < 0.01), though not severe AKI (SHR = 1.33, 95% CI = 0.93-1.91, p = 0.11). Our findings confirm that use of ADT is associated with an increased risk of AKI in patients undergoing definitive RT for prostate cancer. Clinicians should be alert to the potential for renal dysfunction in this population.
Sections du résumé
BACKGROUND
Androgen deprivation therapy (ADT) is frequently utilized in conjunction with radiotherapy (RT) in the definitive management of prostate cancer. Prior studies have suggested an association between ADT use and acute kidney injury (AKI), however, these included heterogeneous populations undergoing a variety of treatments and relied on billing codes to ascertain the incidence of AKI.
METHODS
We analyzed a cohort of 27,868 veterans undergoing definitive RT + /- ADT for prostate cancer between 2001 and 2015 using the Veterans Affairs Informatics and Computing Infrastructure (VINCI). Exposure was defined as use of ADT within one year of diagnosis. The primary outcome was AKI, defined by an increase in serum creatinine to at least 1.5 times the baseline value. AKIs were classified as mild, moderate, or severe in accordance with international guidelines. A multivariate competing risks model was used to account for demographic and oncologic factors as well as medications and procedures known to influence the risk of AKI.
RESULTS
Most (n = 18,754) men received RT alone; 9,114 men received RT + ADT. The incidence of AKI at two years after diagnosis was 10.5% in the RT + ADT group and 7.9% in the RT group (Gray's test p < 0.01). Multivariate analysis confirmed ADT usage was associated with an increased risk for any AKI (SHR = 1.24, 95% CI = 1.14-1.36, p < 0.01). ADT was also associated with an increased risk of mild AKI (SHR = 1.13, 95% CI = 1.01-1.27, p = 0.04) and moderate AKI (SHR = 1.45, 95% CI = 1.20-1.76, p < 0.01), though not severe AKI (SHR = 1.33, 95% CI = 0.93-1.91, p = 0.11).
CONCLUSIONS
Our findings confirm that use of ADT is associated with an increased risk of AKI in patients undergoing definitive RT for prostate cancer. Clinicians should be alert to the potential for renal dysfunction in this population.
Identifiants
pubmed: 34811501
doi: 10.1038/s41391-021-00415-3
pii: 10.1038/s41391-021-00415-3
doi:
Substances chimiques
Androgen Antagonists
0
Androgens
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
276-281Informations de copyright
© 2021. The Author(s), under exclusive licence to Springer Nature Limited.
Références
Mohler JL, Antonarakis ES, Armstrong AJ, D’Amico AV, Davis BJ, Dorff T, et al. Prostate cancer, version 2.2019, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2019;17:479–505.
doi: 10.6004/jnccn.2019.0023
pubmed: 31085757
Nguyen PL, Alibhai SM, Basaria S, D’Amico AV, Kantoff PW, Keating NL, et al. Adverse effects of androgen deprivation therapy and strategies to mitigate them. Eur Urol. 2015;67:825–36.
doi: 10.1016/j.eururo.2014.07.010
pubmed: 25097095
Deka R, Rose BS, Bryant AK, Sarkar RR, Nalawade V, McKay R, et al. Androgen deprivation therapy and depression in men with prostate cancer treated with definitive radiation therapy. Cancer .2019;125:1070–80.
doi: 10.1002/cncr.31982
pubmed: 30748008
Baik SH, Kury FSP, McDonald CJ. Risk of alzheimer’s disease among senior medicare beneficiaries treated with androgen deprivation therapy for prostate cancer. J Clin Oncol. 2017;35:3401–9.
doi: 10.1200/JCO.2017.72.6109
pubmed: 28841388
pmcid: 5648173
Nead KT, Gaskin G, Chester C, Swisher-McClure S, Leeper NJ, Shah NH. Association between androgen deprivation therapy and risk of dementia. JAMA Oncol. 2017;3:49–55.
doi: 10.1001/jamaoncol.2016.3662
pubmed: 27737437
Braga-Basaria M, Dobs AS, Muller DC, Carducci MA, John M, Egan J, et al. Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy. J Clin Oncol. 2006;24:3979–83.
doi: 10.1200/JCO.2006.05.9741
pubmed: 16921050
Molinari C, Battaglia A, Grossini E, Mary DA, Vassanelli C, Vacca G. The effect of testosterone on regional blood flow in prepubertal anaesthetized pigs. J Physiol. 2002;543:365–72.
doi: 10.1113/jphysiol.2002.022756
pubmed: 12181306
pmcid: 2290490
Gandaglia G, Sun M, Hu JC, Novara G, Choueiri TK, Nguyen PL. et al. Gonadotropin-releasing hormone agonists and acute kidney injury in patients with prostate cancer. Eur Urol. 2014;66:1125–32.
doi: 10.1016/j.eururo.2014.01.026
pubmed: 24495466
Kambham N, Markowitz GS, Valeri AM, Lin J, D’Agati VD. Obesity-related glomerulopathy: an emerging epidemic. Kidney Int. 2001;59:1498–509.
doi: 10.1046/j.1523-1755.2001.0590041498.x
pubmed: 11260414
Lapi F, Azoulay L, Niazi MT, Yin H, Benayoun S, Suissa S. Androgen deprivation therapy and risk of acute kidney injury in patients with prostate cancer. JAMA. 2013;310:289–96.
doi: 10.1001/jama.2013.8638
pubmed: 23860987
Kellum JA, Lameire N, Aspelin P, Barsoum RS, Burdmann EA, Goldstein SL, et al. Kidney disease: improving global outcomes (KDIGO) acute kidney injury work group. KDIGO clinical practice guideline for acute kidney injury. Kidney Int Suppl. 2012;2:1–138.
Duvall S What is VINCI?: US Department of Veterans Affairs; 2016 [Available from: https://www.hsrd.research.va.gov/for_researchers/cyber_seminars/archives/video_archive.cfm?SessionID=1143 .
Tominey S, Timmins A, Lee R, Walsh TS, Lone NI. Community prescribing of potentially nephrotoxic drugs and risk of acute kidney injury requiring renal replacement therapy in critically ill adults: a national cohort study. J Intensive Care Soc. 2020;0:1–9.
Perazella MA. Drug-induced acute kidney injury: diverse mechanisms of tubular injury. Curr Opin Crit Care. 2019;25:550–7.
doi: 10.1097/MCC.0000000000000653
pubmed: 31483318
Moos SI, van Vemde DN, Stoker J, Bipat S. Contrast induced nephropathy in patients undergoing intravenous (IV) contrast enhanced computed tomography (CECT) and the relationship with risk factors: a meta-analysis. Eur J Radio. 2013;82:e387–99.
doi: 10.1016/j.ejrad.2013.04.029
Uchino S, Kellum JA, Bellomo R, Doig GS, Morimatsu H, Morgera S, et al. Acute renal failure in critically ill patients: a multinational, multicenter study. JAMA. 2005;294:813–8.
doi: 10.1001/jama.294.7.813
pubmed: 16106006
Mercado MG, Smith DK, Guard EL. Acute kidney injury: diagnosis and management. Am Fam Physician. 2019;100:687–94.
pubmed: 31790176
Schaffzin JK, Dodd CN, Nguyen H, Schondelmeyer A, Campanella S, Goldstein SL. Administrative data misclassifies and fails to identify nephrotoxin-associated acute kidney injury in hospitalized children. Hosp Pediatr. 2014;4:159–66.
doi: 10.1542/hpeds.2013-0116
pubmed: 24785560
Logan R, Davey P, De Souza N, Baird D, Guthrie B, Bell S. Assessing the accuracy of ICD-10 coding for measuring rates of and mortality from acute kidney injury and the impact of electronic alerts: an observational cohort study. Clin Kidney J. 2020;13:1083–90.
doi: 10.1093/ckj/sfz117
pubmed: 33391753
Cartin-Ceba R, Kashiouris M, Plataki M, Kor DJ, Gajic O, Casey ET. Risk factors for development of acute kidney injury in critically ill patients: a systematic review and meta-analysis of observational studies. Crit Care Res Pract. 2012; 2012: 691013.
Grams ME, Sang Y, Ballew SH, Gansevoort RT, Kimm H, Kovesdy CP, et al. A Meta-analysis of the association of estimated GFR, albuminuria, age, race, and sex with acute kidney injury. Am J Kidney Dis. 2015;66:591–601.
doi: 10.1053/j.ajkd.2015.02.337
pubmed: 25943717
pmcid: 4584180
Grams ME, Matsushita K, Sang Y, Estrella MM, Foster MC, Tin A, et al. Explaining the racial difference in AKI incidence. J Am Soc Nephrol. 2014;25:1834–41.
doi: 10.1681/ASN.2013080867
pubmed: 24722442
pmcid: 4116065
Sawhney S, Fraser SD. Epidemiology of AKI: utilizing large databases to determine the burden of AKI. Adv Chronic Kidney Dis. 2017;24:194–204.
doi: 10.1053/j.ackd.2017.05.001
pubmed: 28778358
pmcid: 5648688
Orth SR, Ritz E, Schrier RW. The renal risks of smoking. Kidney Int. 1997;51:1669–77.
doi: 10.1038/ki.1997.232
pubmed: 9186854
Arany I, Grifoni S, Clark JS, Csongradi E, Maric C, Juncos LA. Chronic nicotine exposure exacerbates acute renal ischemic injury. Am J Physiol Ren Physiol. 2011;301:F125–33.
doi: 10.1152/ajprenal.00041.2011
Parolari A, Pesce LL, Pacini D, Mazzanti V, Salis S, Sciacovelli C, et al. Risk factors for perioperative acute kidney injury after adult cardiac surgery: role of perioperative management. Ann Thorac Surg. 2012;93:584–91.
doi: 10.1016/j.athoracsur.2011.09.073
pubmed: 22269725
Coca SG, Singanamala S, Parikh CR. Chronic kidney disease after acute kidney injury: a systematic review and meta-analysis. Kidney Int. 2012;81:442–8.
doi: 10.1038/ki.2011.379
pubmed: 22113526
Kurzhagen JT, Dellepiane S, Cantaluppi V, Rabb H. AKI: an increasingly recognized risk factor for CKD development and progression. J Nephrol. 2020;33:1171–87.
doi: 10.1007/s40620-020-00793-2
pubmed: 32651850